NAD+

Nicotinamide Adenine Dinucleotide (NAD+) is an essential coenzyme present in virtually every living cell. It plays a central role in cellular energy production by transferring electrons during glycolysis, the tricarboxylic acid (TCA) cycle, and mitochondrial oxidative phosphorylation. NAD+ also serves as a necessary substrate for enzymes involved in DNA repair, cellular stress responses, metabolic regulation, and other maintenance processes, including sirtuins, poly(ADP-ribose) polymerases (PARPs), and CD38. These diverse functions have made NAD+ an important research target in aging biology, mitochondrial dysfunction, metabolic disease, and neurodegenerative conditions.

Scientists are investigating whether supporting NAD+ metabolism can improve cellular resilience and health during aging or disease. Human studies have demonstrated that oral precursors such as nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) can increase selected NAD-related biomarkers, while smaller intravenous NAD+ studies have examined pharmacokinetics, tolerability, and short-term metabolic measurements. However, raising circulating NAD+ does not automatically establish greater cellular energy production, improved cognition, faster exercise recovery, or longer lifespan. Evidence for consistent age-related NAD+ depletion in humans is also more limited and tissue-dependent than commonly claimed. Injectable NAD+ is not FDA-approved for anti-aging or wellness, and its optimal dosing, clinical effectiveness, and long-term safety remain uncertain.

NAD+ is essential for cellular metabolism because it participates in electron-transfer reactions and supplies substrate for enzymes involved in cell maintenance. Its biological effects depend on the continuous conversion, consumption, and regeneration of NAD-related molecules.

1. Cellular Energy Production

• NAD+ accepts electrons during metabolic reactions, becoming its reduced form, NADH.
• During glycolysis and the TCA cycle, this process helps extract chemical energy from carbohydrates, fats, and other nutrients.
• NADH then transfers electrons to the mitochondrial electron transport chain.
• The resulting electrochemical gradient supports ATP synthesis, supplying energy for cellular functions.
• NAD+ is therefore essential for energy production, but injecting additional NAD+ has not been shown to automatically increase ATP production in healthy people.

2. The NAD+/NADH Redox Cycle

• NAD+ is the oxidized form, while NADH is the reduced form.
• Cells continually convert NAD+ and NADH during energy metabolism.
• The balance between these forms influences metabolic reactions and cellular redox status.
• The NAD+/NADH ratio can differ substantially between tissues and cellular compartments.

3. Sirtuin Signaling

• Sirtuins are NAD+-dependent enzymes involved in protein modification and cellular regulation.
• They influence metabolism, responses to cellular stress, chromatin-related processes, and mitochondrial function.
• Because sirtuins require NAD+, researchers are interested in whether NAD+ availability affects their activity.
• However, increasing NAD+ levels does not guarantee increased activity of every sirtuin or improved human longevity.

4. PARP Enzymes and DNA Repair

• Poly(ADP-ribose) polymerases, or PARPs, participate in cellular responses to DNA damage.
• PARPs consume NAD+ to generate ADP-ribose-based signaling structures involved in DNA-repair processes.
• Substantial PARP activation can increase cellular NAD+ consumption.
• Researchers are investigating whether altered NAD+ metabolism contributes to impaired cellular resilience under stress.

5. CD38 and NAD+ Consumption

• CD38 is an enzyme that consumes NAD+ and participates in calcium-related cellular signaling.
• Preclinical studies suggest that CD38 activity can change with inflammation and aging-related processes.
• In animal models, elevated NAD+ consumption through CD38 has been associated with lower tissue NAD+ availability.
• The clinical implications of targeting CD38 or supplementing NAD+ in humans remain under investigation.

6. NAD+ Biosynthesis and Salvage

• Cells obtain NAD+ through pathways using vitamin B3-related compounds and tryptophan.
• Nicotinamide can be recycled through the NAD+ salvage pathway, which involves the enzyme NAMPT.
• Nicotinamide riboside (NR) can enter NAD+ biosynthesis through nicotinamide riboside kinase enzymes.
• Nicotinamide mononucleotide (NMN) is another intermediate in NAD+ metabolism.
• These pathways explain why oral precursors may raise blood NAD-related biomarkers without requiring intact NAD+ to enter cells directly.

7. Extracellular NAD+ Metabolism

• NAD+ administered into the bloodstream may be rapidly metabolized by extracellular enzymes.
• Breakdown products can include nicotinamide, ADP-ribose-related molecules, and other NAD+ metabolites.
• These metabolites may participate in subsequent cellular uptake and resynthesis pathways.
• A 2019 human intravenous pharmacokinetic study demonstrated complex plasma and urine metabolite changes during NAD+ infusion.
• Intravenous administration places NAD+ directly in the circulation, but this does not mean the intact coenzyme is immediately transported into every cell.

8. NAD+ and the Aging Process

• Some animal and human tissue studies have reported lower NAD+ availability under aging-related or metabolic stress conditions.
• However, findings in humans vary by tissue, disease state, and measurement method.
• A 2026 investigation across seven independent human cohorts found that whole-blood NAD+ concentrations remained relatively stable with age.
• This finding challenges the assumption that all humans experience a uniform systemic NAD+ decline beginning at a specific age.

The Key Difference: NAD+ is a fundamental component of normal cellular metabolism, not a stimulant, anabolic compound, or direct mitochondrial energy injection. Its essential biological role does not establish that administering additional NAD+ improves health when normal metabolism is functioning adequately.

Researchers are interested in NAD+ because it participates in numerous biological processes involving energy metabolism, cellular repair, metabolic regulation, and responses to stress.

• Mitochondrial Function: NAD+ and NADH participate directly in energy-producing metabolic pathways.
• DNA Repair: NAD+ is required by PARP enzymes involved in cellular responses to DNA damage.
• Sirtuin Biology: NAD+-dependent sirtuins influence metabolism and cellular stress-related processes.
• Healthy Aging: Changes in NAD+ metabolism may contribute to selected age-related biological processes.
• Metabolic Health: NAD+ pathways are involved in glucose metabolism, lipid metabolism, and insulin-related physiology.
• Neuroprotection: Brain metabolism and neuronal survival depend on appropriate NAD+ availability.
• Cardiovascular Research: Scientists are investigating relationships among NAD+ metabolism, vascular function, and cardiometabolic disease.
• Exercise Physiology: Energy metabolism and mitochondrial adaptation involve NAD-related pathways.
• Inflammation: CD38 and other NAD-consuming enzymes participate in immune-related signaling.
• Drug Development: Researchers are comparing direct NAD+ administration with precursors, salvage-pathway interventions, and other strategies for modifying cellular NAD+ availability.

Research Limitation: The fact that NAD+ is essential to these pathways does not establish that injections or supplements improve each pathway in people who are not deficient. The strongest clinical evidence currently concerns changes in NAD-related biomarkers rather than broad health improvements.

NAD+ is essential for cellular health, but the clinical effects of administering additional NAD+ must be distinguished from its normal physiological functions. Human studies involving direct intravenous NAD+ remain small, while oral NAD+ precursors have been evaluated in a larger number of randomized trials.

• Cellular Energy: NAD+ is indispensable for normal ATP production. Increased energy or reduced fatigue following NAD+ injection has not been reliably demonstrated in controlled trials.
• NAD+ Metabolism: Human intravenous studies have documented changes in NAD+ and related metabolites during infusion.
• Oral Precursor Activity: Human trials demonstrate that NR and NMN can increase selected NAD-related biomarkers.
• Metabolic Health: Some precursor studies report changes in selected metabolic outcomes, but results are inconsistent.
• Cognitive Function: Preclinical findings provide biological rationale, but human evidence does not establish cognitive enhancement from injected NAD+.
• Physical Performance: Human studies have not demonstrated consistent improvements in muscle strength or endurance from direct NAD+ administration.
• DNA Repair: NAD+ is required for normal DNA-repair signaling, but additional injected NAD+ has not been demonstrated to improve clinically meaningful DNA-repair outcomes.
• Cardiovascular Health: Relationships between NAD+ metabolism and vascular function are under investigation; plaque reversal has not been demonstrated from NAD+ injections.
• Healthy Aging: No human trial has established that NAD+ injections slow biological aging or extend lifespan.

Notable 2019 Human Infusion Study: A small study included eight participants receiving 750 mg of intravenous NAD+ over six hours and three saline controls. Plasma NAD+ and several metabolites did not increase substantially during the first two hours. Later measurements showed changes in circulating metabolites and urinary excretion. The study investigated pharmacokinetics rather than improvements in energy, cognition, or longevity.

Notable 2026 Human Tolerability Study: A retrospective pilot study compared six people receiving 500 mg intravenous NAD+ on four consecutive days with eight receiving intravenous nicotinamide riboside (NR). The NAD+ group experienced more pronounced gastrointestinal symptoms, increased heart rate, and chest pressure during infusions. These symptoms prolonged infusion times.

2026 Systematic Review: A review of 113 preclinical and human intervention studies identified 33 human studies, most involving NAD+ precursors. NR and NMN generally increased relevant biomarkers, but effects on function, metabolism, vascular outcomes, and healthspan remained inconsistent. No eligible clinical outcomes trial established anti-aging or wellness benefits from intravenous or intramuscular NAD+ itself.

2026 Aging Research: An investigation across seven human cohorts found that whole-blood NAD+ levels remained relatively stable with age and common lifestyle interventions. The results challenge the use of blood NAD+ concentration as a universal marker of biological aging.

Important Clinical Distinction: The benefits of correcting a genuine vitamin B3 deficiency should not be confused with claims that high-dose NAD+ therapy produces additional benefits in people with adequate nutritional status.

Research Perspective: NAD+ biology is strongly established, but clinical effectiveness of NAD+ injection for fatigue, cognitive performance, weight management, tissue repair, and longevity remains unproven.

NAD+ has been administered to humans in small intravenous pharmacokinetic and tolerability studies. Very limited exploratory research has also examined intramuscular and subcutaneous administration. However, no FDA-approved injectable dose or validated treatment schedule exists for energy enhancement, cognitive performance, metabolic optimization, or longevity.

Published Human Research and Community-Reported Dosing

Community-Reported Subcutaneous Escalation Example

Administration Route Considerations

• Intravenous (IV): Places the compound directly into circulation. However, systemic delivery does not guarantee intact NAD+ reaches intracellular compartments such as mitochondria.
• Intramuscular (IM): Examined in a small 2026 exploratory pilot; long-term safety, bioavailability, and dose-response remain uncertain.
• Subcutaneous (SubQ): Examined in a small short-duration exploratory pilot. There is no established evidence supporting multiweek daily maintenance protocols.
• Intranasal: Commercial and community formulations exist, but reliable human pharmacokinetic and neurological efficacy data remain lacking.
• Oral NAD+: Intact oral NAD+ has a less established human clinical evidence base than oral NR and NMN. These substances should not be assumed to have equivalent pharmacokinetics.

Research Reconstitution and Concentration

NAD+ research materials may be supplied as lyophilized powder in 500 mg or 1,000 mg containers. Concentration calculations use the basic relationship between total compound mass and solution volume. However, mathematical accuracy does not establish that a mixture is suitable for injection.

Injectable preparations require verified pharmaceutical-grade ingredients, appropriate formulation pH and osmolality, sterility, endotoxin control, chemical stability, and compatibility testing. Simply adding bacteriostatic water to research-market powder does not establish that these requirements have been met.

Storage: No universal refrigeration period, post-reconstitution beyond-use date, or freeze-thaw protocol can be established for all NAD+ formulations. Stability depends on product composition, packaging, temperature, light exposure, pH, and validated manufacturing data.

Important Dose Distinction: A 100 mg dose of NR is not equivalent to 100 mg of NAD+, and the clinical findings of oral NR or NMN cannot be transferred to directly injected NAD+.

Research Perspective: The amounts above are included for educational comparison. Human NAD+ studies establish limited short-term exposure and tolerability information, not a recommended therapeutic regimen for longevity or metabolic enhancement.

No clinically validated long-term treatment cycle or washout period exists for directly administered NAD+. Published human studies generally evaluated single infusions or short treatment periods, while community and commercial protocols describe substantially longer exposure.

• 2019 Pharmacokinetic Research: Evaluated a single six-hour intravenous infusion.
• 2026 Intravenous Tolerability Research: Evaluated four consecutive daily infusions, with follow-up over 30 days.
• 2026 Injectable Pilot: Evaluated three consecutive days of injections followed by a seven-day observation or washout interval.
• Oral NR / NMN Research: Numerous studies have investigated supplementation over several weeks to months, but these are different substances.
• Community Short Courses: Two to four weeks of NAD+ injections are sometimes described.
• Common Community Cycles: Eight to twelve weeks of daily injections are frequently discussed.
• Community Washout Periods: Four to six weeks off between cycles are sometimes recommended informally.
• Intermittent Community Use: Once- or twice-weekly maintenance schedules are also discussed.
• Long-Term Exposure: The cumulative safety and clinical effectiveness of repeated injections over months or years remain unknown.

Important Limitation: No human clinical evidence establishes that cycling prevents tolerance, restores NAD+ biosynthesis, protects the liver or kidneys, or improves longevity outcomes.

Research Consideration: NAD+ metabolism is dynamically regulated by synthesis, consumption, and recycling. No research demonstrates that the body requires routine injectable NAD+ cycles to maintain healthy cellular metabolism.

NAD+ is frequently discussed alongside nutritional precursors, compounds affecting mitochondrial function, and experimental peptides associated with cellular repair. These combinations are generally based on distinct biological pathways rather than controlled clinical trials demonstrating additional benefits.

Research Perspective: NAD+ metabolism connects with numerous biochemical pathways, but biochemical interaction does not prove that adding multiple compounds improves clinical outcomes.

Important Distinction: Theoretical synergy does not establish that multiple experimental compounds can be safely mixed into a single injectable preparation or administered together.

Injectable NAD+ has been evaluated in relatively small human studies. Reported short-term adverse experiences include gastrointestinal symptoms, chest pressure, and heart-rate changes during intravenous infusion. In addition, the FDA has identified serious safety concerns involving contamination of certain compounded injectable NAD+ products.

Important 2026 Tolerability Finding: In a retrospective study involving six intravenous NAD+ recipients, moderate to severe gastrointestinal discomfort, increased heart rate, and chest pressure were observed during infusions. Infusion times were longer than for the group receiving intravenous nicotinamide riboside.

Important FDA Safety Alert: The FDA has received reports of severe chills, shaking, vomiting, and fatigue following use of injectable NAD+ products. Some individuals required medical treatment. The agency noted that these reactions were consistent with excessive endotoxin contamination.

Product Quality Distinction: Food-grade or dietary supplement-grade NAD+ ingredients are not necessarily suitable for manufacturing sterile injectable medications. Sterility and endotoxin control must be established independently of the compound's chemical identity.

Monthly Dose Claims: No credible human clinical evidence establishes a universal threshold such as 3,000 mg per month above which NAD+ injections predictably cause liver damage, kidney disease, or vascular complications. The absence of a validated threshold does not mean higher cumulative exposure is safe.

Important Clinical Distinction: Some acute infusion symptoms may reflect administration-related pharmacology, while others may be caused by contamination or unsuitable formulations. These should not be treated as interchangeable mechanisms.

Research Perspective: The biological importance of NAD+ does not make injectable NAD+ inherently safe. Formulation quality, administration route, short-term tolerability, and long-term risks all require careful evaluation.

NAD+ is an essential endogenous molecule, but injectable NAD+ therapy has not completed sufficient clinical development to establish a comprehensive FDA-approved contraindication profile for longevity, metabolic enhancement, or general wellness.

• Pregnancy and Breastfeeding: Safety of high-dose injectable NAD+ during pregnancy and lactation has not been established.
• Active Cancer: NAD+ metabolism supports normal cell survival and is also relevant to cancer-cell metabolism. Clinical effects of supplemental NAD+ during malignancy remain uncertain.
• Cancer Treatment: Potential interactions with therapies targeting PARPs, NAD+ metabolism, or other cellular survival pathways require specialist evaluation.
• Cardiovascular Disease: Chest pressure and heart-rate changes have been reported during intravenous NAD+ administration.
• Uncontrolled Blood Pressure: Cardiovascular responses and potential interactions with antihypertensive medications have not been adequately studied.
• Kidney Disease: Human clearance, metabolite handling, and long-term renal safety require additional investigation.
• Liver Disease: Long-term safety at high cumulative doses is unknown. The liver plays an important role in NAD+ precursor metabolism.
• Diabetes: NAD+ metabolism is closely associated with glucose regulation, but injections have not been demonstrated to improve insulin sensitivity or glycemic control.
• Antidepressants / Psychiatric Medications: Adequate interaction studies are lacking. No evidence establishes a universal contraindication to all antidepressants.
• Anticoagulants: Clinically important interactions with injected NAD+ have not been established, but procedure-related bleeding or bruising may be relevant.
• Alcohol Use Disorder: NAD+ infusions have not been established as a treatment for alcohol dependence, detoxification, or withdrawal.
• Severe Fatigue: Persistent fatigue may be caused by anemia, sleep disorders, thyroid disease, medication effects, or other conditions requiring appropriate assessment.
• Concurrent Experimental Compounds: Combining several unapproved substances may increase uncertainty regarding adverse reactions and drug interactions.
• Unregulated Injectable Products: Endotoxin contamination, microbial contamination, inappropriate pH, inaccurate concentration, and unsuitable ingredients can present serious risks.

Regulatory Caution: NAD+ injections are not FDA-approved for anti-aging, weight management, cognitive enhancement, chronic fatigue, mitochondrial optimization, or addiction treatment. The FDA has specifically warned about inappropriate ingredients used to produce compounded sterile NAD+ products.

Cancer Biology Distinction: NAD+ is essential for normal cells and many cancer cells. Its involvement in cell survival does not establish that supplemental NAD+ causes cancer, but it also does not establish safety during active cancer treatment.

Interaction Distinction: Blanket claims that NAD+ must never be used with antidepressants, blood pressure medications, or anticoagulants are not supported by established clinical interaction studies. The relevant concerns depend on the medical condition, medications, and administration setting.

Medical Consideration: Chest pain, breathing difficulty, severe chills, shaking, fainting, or persistent vomiting following an injection or infusion requires prompt medical evaluation rather than assuming the reaction is an expected part of NAD+ therapy.

Research investigating NAD+ interventions has measured blood and cellular NAD-related metabolites, metabolic health, safety markers, and selected functional outcomes. However, no validated testing panel or monitoring interval establishes the effectiveness or long-term safety of injectable NAD+ therapy.

Important 2026 Finding: A study across seven human cohorts found that whole-blood NAD+ levels remained relatively stable with age and lifestyle interventions. This challenges the use of a single blood NAD+ result as a reliable indicator of biological age.

Measurement Consideration: NAD+ concentrations differ among plasma, whole blood, individual cell types, and tissues. Laboratory handling and analytical methods can also affect results.

Functional Outcomes: A higher blood NAD+ concentration does not automatically indicate improved mitochondrial performance, cognition, sleep, or physical endurance. Those benefits require independent measurement.

Safety Consideration: Normal liver and kidney measurements do not establish that an injectable NAD+ formulation is sterile, endotoxin-free, or safe for repeated use.

Important Limitation: No commercially available NAD+ blood test or biomarker panel has been validated to guide an optimal injectable dose for anti-aging or wellness.